Update on the Genetics of Androgenetic Alopecia, Female Pattern Hair Loss, and Alopecia Areata: Implications for Molecular Diagnostic Testing

Seminars in Cutaneous Medicine and Surgery

Volumn 31, Issue 4, 2012, Pages 258-266

  Yazdan, Pedram ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alopecia areata; Androgenetic alopecia; Female pattern hair loss; Genetics; Molecular diagnostic testing; Therapy

Indexed keywords

ABATACEPT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; XEDAR RECEPTOR;

ALOPECIA; ALOPECIA AREATA; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE PATTERN HAIR LOSS; HAIR GROWTH; HAIR LOSS; HEREDITY; HUMAN; MALE TYPE ALOPECIA; MOLECULAR DIAGNOSIS; PATHOGENESIS; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

AGE FACTORS; ALOPECIA; ALOPECIA AREATA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAIR; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; SEX FACTORS; TESTOSTERONE;

EID: 84869846337     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.1016/j.sder.2012.08.003     Document Type: Review

References (96)

1. Alkhalifah A., Alsantali A., Wang E., et al. Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010, 62:177-188. quiz 89-90.
2. Alfonso M., Richter-Appelt H., Tosti A., et al. The psychosocial impact of hair loss among men: A multinational European study. Curr Med Res Opin 2005, 21:1829-1836.
3. Petukhova L., Cabral R.M., Mackay-Wiggan J., et al. The genetics of alopecia areata: What's new and how will it help our patients?. Dermatol Ther 2011, 24:326-336.
4. Ellis J. Future directions: Gene polymorphism diagnostics relavant to hair. Aging Hair 2010, 291-332. Springer, London. R. Trueb, D. Tobin (Eds.).
5. Dy L.C., Whiting D.A. Histopathology of alopecia areata, acute and chronic: Why is it important to the clinician?. Dermatol Ther 2011, 24:369-374.
6. Eudy G., Solomon A.R. The histopathology of noncicatricial alopecia. Semin Cutan Med Surg 2006, 25:35-40.
7. Han A., Mirmirani P. Clinical approach to the patient with alopecia. Semin Cutan Med Surg 2006, 25:11-23.
8. Hoss D.M., Grant-Kels J.M. Diagnosis: Alopecia areata or not?. Semin Cutan Med Surg 1999, 18:84-90.
9. Stefanato C.M. Histopathology of alopecia: A clinicopathological approach to diagnosis. Histopathology 2010, 56:24-38.
10. Trueb R.M., Tobin D.J. Aging Hair 2010, 270. Springer, Berlin.
11. Tosti A., Bellavista S., Iorizzo M. Alopecia areata: A long term follow-up study of 191 patients. J Am Acad Dermatol 2006, 55:438-441.
12. Rhodes T., Girman C.J., Savin R.C., et al. Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg 1998, 24:1330-1332.
13. Norwood O.T. Male pattern baldness: Classification and incidence. South Med J 1975, 68:1359-1365.
14. Hamilton J.B. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci 1951, 53:708-728.
15. Gan D.C., Sinclair R.D. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc 2005, 10:184-189.
16. Hamilton J.B. Effect of castration in adolescent and young adult males upon further changes in the proportions of bare and hairy scalp. J Clin Endocrinol Metab 1960, 20:1309-1318.
17. Kaufman K.D. Androgens and alopecia. Mol Cell Endocrinol 2002, 198:89-95.
18. Jenkins E.P., Andersson S., Imperato-McGinley J., et al. Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. J Clin Invest 1992, 89:293-300.
19. Olsen E.A. Female pattern hair loss. J Am Acad Dermatol 2001, 45(Suppl 3):S70-S80.
20. Birch M.P., Messenger J.F., Messenger A.G. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol 2001, 144:297-304.
21. Orme S., Cullen D.R., Messenger A.G. Diffuse female hair loss: Are androgens necessary?. Br J Dermatol 1999, 141:521-523.
22. Lynfield Y.L. Effect of pregnancy on the human hair cycle. J Invest Dermatol 1960, 35:323-327.
23. Simpson D., Curran M.P., Perry C.M. Letrozole: A review of its use in postmenopausal women with breast cancer. Drugs 2004, 64:1213-1230.
24. Ohnemus U., Uenalan M., Inzunza J., et al. The hair follicle as an estrogen target and source. Endocr Rev 2006, 27:677-706.
25. Oh H.S., Smart R.C. An estrogen receptor pathway regulates the telogen-anagen hair follicle transition and influences epidermal cell proliferation. Proc Natl Acad Sci USA 1996, 93:12525-12530.
26. Yip L., Zaloumis S., Irwin D., et al. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol 2009, 161:289-294.
27. Nyholt D.R., Gillespie N.A., Heath A.C., et al. Genetic basis of male pattern baldness. J Invest Dermatol 2003, 121:1561-1564.
28. Ellis J.A., Harrap S.B. The genetics of androgenetic alopecia. Clin Dermatol 2001, 19:149-154.
29. Ellis J.A., Stebbing M., Harrap S.B. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol 1998, 110:849-853.
30. Ellis J.A., Stebbing M., Harrap S.B. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001, 116:452-455.
31. Sawaya M.E., Shalita A.R. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 1998, 3:9-15.
32. Hillmer A.M., Hanneken S., Ritzmann S., et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet 2005, 77:140-148.
33. Ellis J.A., Scurrah K.J., Cobb J.E., et al. Baldness and the androgen receptor: The AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. Hum Genet 2007, 121:451-457.
34. Hillmer A.M., Brockschmidt F.F., Hanneken S., et al. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet 2008, 40:1279-1281.
35. Hillmer A.M., Flaquer A., Hanneken S., et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet 2008, 82:737-743.
36. Prodi D.A., Pirastu N., Maninchedda G., et al. EDA2R is associated with androgenetic alopecia. J Invest Dermatol 2008, 128:2268-2270.
37. Richards J.B., Yuan X., Geller F., et al. Male-pattern baldness susceptibility locus at 20p11. Nat Genet 2008, 40:1282-1284.
38. Cobb J.E., White S.J., Harrap S.B., et al. Androgen receptor copy number variation and androgenetic alopecia: A case-control study. PLoS One 2009, 4:e5081.
39. Cobb J.E., Zaloumis S.G., Scurrah K.J., et al. Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene. Exp Dermatol 2010, 19:1026-1028.
40. Bubulya A., Wise S.C., Shen X.Q., et al. C-Jun can mediate androgen receptor-induced transactivation. J Biol Chem 1996, 271:24583-24589.
41. Brockschmidt F.F., Heilmann S., Ellis J.A., et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol 2011, 165:1293-1302.
42. el-Samahy M.H., Shaheen M.A., Saddik D.E., et al. Evaluation of androgen receptor gene as a candidate gene in female androgenetic alopecia. Int J Dermatol 2009, 48:584-587.
43. Ali I., Wojnarowska F. Physiological changes in scalp, facial and body hair after the menopause: A cross-sectional population-based study of subjective changes. Br J Dermatol 2011, 164:508-513.
44. Haiman C.A., Dossus L., Setiawan V.W., et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007, 67:1893-1897.
45. Yip L., Zaloumis S., Irwin D., et al. Association analysis of oestrogen receptor beta gene (ESR2) polymorphisms with female pattern hair loss. Br J Dermatol 2012, 166:1131-1134.
46. Tang L., Bernardo O., Bolduc C., et al. The expression of insulin-like growth factor 1 in follicular dermal papillae correlates with therapeutic efficacy of finasteride in androgenetic alopecia. J Am Acad Dermatol 2003, 49:229-233.
47. Wakisaka N., Taira Y., Ishikawa M., et al. Effectiveness of finasteride on patients with male pattern baldness who have different androgen receptor gene polymorphism. J Investig Dermatol Symp Proc 2005, 10:293-294.
48. Sato A., Arima Y., Kojima Y., et al. Correlation between polymorphic CAG-repeats in the androgen receptor gene and therapeutic efficacy of finasteride in androgenetic alopecia. Skin Surg 2008, 17:80-86.
49. Yamazaki M., Sato A., Toyoshima K.E., et al. Polymorphic CAG repeat numbers in the androgen receptor gene of female pattern hair loss patients. J Dermatol 2011, 38:680-684.
50. Keene S., Goren A. Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatol Ther 2011, 24:296-300.
51. Kaufman K.D., Rotonda J., Shah A.K., et al. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol 2008, 18:400-406.
52. HairDx Accessed July 17, 2012. http://www.hairdx.com.
53. McMichael A.J., Pearce D.J., Wasserman D., et al. Alopecia in the United States: Outpatient utilization and common prescribing patterns. J Am Acad Dermatol 2007, 57(Suppl 2):S49-S51.
54. Safavi K. Prevalence of alopecia areata in the first national health and nutrition examination survey. Arch Dermatol 1992, 128:702.
55. Finner A.M. Alopecia areata: Clinical presentation, diagnosis, and unusual cases. Dermatol Ther 2011, 24:348-354.
56. Barahmani N., Schabath M.B., Duvic M., et al. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 2009, 61:581-591. National Alopecia Areata Registry.
57. Chu S.Y., Chen Y.J., Tseng W.C., et al. Comorbidity profiles among patients with alopecia areata: The importance of onset age, a nationwide population-based study. J Am Acad Dermatol 2011, 65:949-956.
58. Gilhar A., Paus R., Kalish R.S. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest 2007, 117:2019-2027.
59. Delamere F.M., Sladden M.M., Dobbins H.M., et al. Interventions for alopecia areata. Cochrane Database Syst Rev 2008, 2. CD004413.
60. Miteva M., Tosti A. Treatment options for alopecia: An update, looking to the future. Expert Opin Pharmacother 2012, 13:1271-1281.
61. Paus R., Nickoloff B.J., Ito T. A "hairy" privilege. Trends Immunol 2005, 26:32-40.
62. Paus R., Slominski A., Czarnetzki B.M. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb?. Yale J Biol Med 1993, 66:541-554.
63. Ito T., Ito N., Bettermann A., et al. Collapse and restoration of MHC class-I-dependent immune privilege: Exploiting the human hair follicle as a model. Am J Pathol 2004, 164:623-634.
64. Siebenhaar F., Sharov A.A., Peters E.M., et al. Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (alopecia areata). J Invest Dermatol 2007, 127:1489-1497.
65. Ito T., Ito N., Saatoff M., et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 2008, 128:1196-1206.
66. Gilhar A., Landau M., Assy B., et al. Mediation of alopecia areata by cooperation between CD4+ and CD8+ T lymphocytes: Transfer to human scalp explants on Prkdc(scid) mice. Arch Dermatol 2002, 138:916-922.
67. Gilhar A., Ullmann Y., Berkutzki T., et al. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 1998, 101:62-67.
68. McElwee K.J., Freyschmidt-Paul P., Hoffmann R., et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol 2005, 124:947-957.
69. McElwee K.J., Spiers E.M., Oliver R.F. In vivo depletion of CD8+ T cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol 1996, 135:211-217.
70. Petukhova L., Duvic M., Hordinsky M., et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010, 466:113-117.
71. Natarajan K., Dimasi N., Wang J., et al. Structure and function of natural killer cell receptors: Multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 2002, 20:853-885.
72. McDonagh A.J., Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 2002, 27:405-409.
73. Jackow C., Puffer N., Hordinsky M., et al. Alopecia areata and cytomegalovirus infection in twins: Genes versus environment?. J Am Acad Dermatol 1998, 38:418-425.
74. Sundberg J.P., Silva K.A., Li R., et al. Adult-onset alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model. J Invest Dermatol 2004, 123:294-297.
75. Goh C., Finkel M., Christos P.J., et al. Profile of 513 patients with alopecia areata: Associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 2006, 20:1055-1060.
76. Colombe B.W., Price V.H., Khoury E.L., et al. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad Dermatol 1995, 33:757-764.
77. Martinez-Mir A., Zlotogorski A., Gordon D., et al. Genome-wide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 2007, 80:316-328.
78. Gregersen P.K., Olsson L.M. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 2009, 27:363-391.
79. Zhernakova A., van Diemen C.C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009, 10:43-55.
80. Muto M., Deguchi H., Tanaka A., et al. Association between T-lymphocyte regulatory gene CTLA4 single nucleotide polymorphism at position 49 in exon 1 and HLA-DRB1*08 in Japanese patients with psoriasis vulgaris. J Dermatol Sci 2011, 62:70-71.
81. Singh T.P., Schön M.P., Wallbrecht K., et al. 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010, 184:7257-7267.
82. Forstbauer L.M., Brockschmidt F.F., Moskvina V., et al. Genome-wide pooling approach identifies SPATA5 as a new susceptibility locus for alopecia areata. Eur J Hum Genet 2012, 20:326-332.
83. Jagielska D., Redler S., Brockschmidt F.F., et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol 2012, 132:2192-2197.
84. Beghé B., Hall I.P., Parker S.G., et al. Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease. Allergy 2010, 65:474-481.
85. Bottema R.W., Nolte I.M., Howard T.D., et al. Interleukin 13 and interleukin 4 receptor-α polymorphisms in rhinitis and asthma. Int Arch Allergy Immunol 2010, 153:259-267.
86. Bowes J., Eyre S., Flynn E., et al. Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Ann Rheum Dis 2011, 70:1016-1019.
87. Martínez A., Perdigones N., Cénit M.C., et al. Chromosomal region 16p13: Further evidence of increased predisposition to immune diseases. Ann Rheum Dis 2010, 69:309-311.
88. Nischwitz S., Cepok S., Kroner A., et al. More CLEC16A gene variants associated with multiple sclerosis. Acta Neurol Scand 2011, 123:400-406.
89. Zoledziewska M., Costa G., Pitzalis M., et al. Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes Immun 2009, 10:15-17.
90. Lueking A., Huber O., Wirths C., et al. Profiling of alopecia areata autoantigens based on protein microarray technology. Mol Cell Proteomics 2005, 4:1382-1390.
91. Subramanya R.D., Coda A.B., Sinha A.A. Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures. Genomics 2010, 96:146-153.
92. Coda A.B., Qafalijaj Hysa V., Seiffert-Sinha K., et al. Peripheral blood gene expression in alopecia areata reveals molecular pathways distinguishing heritability, disease and severity. Genes Immun 2010, 11:531-541.
93. Coda A.B., Sinha A.A. Integration of genome-wide transcriptional and genetic profiles provides insights into disease development and clinical heterogeneity in alopecia areata. Genomics 2011, 98:431-439.
94. John K.K., Brockschmidt F.F., Redler S., et al. Genetic variants in CTLA4 are strongly associated with alopecia areata. J Invest Dermatol 2011, 131:1169-1172.
95. Gilhar A., Etzioni A., Paus R. Alopecia areata. N Engl J Med 2012, 366:1515-1525.
96. Carroll J.M., McElwee K.J., E King L., et al. Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol 2002, 119:392-402.